Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards
- 1 July 2008
- journal article
- research article
- Published by Cambridge University Press (CUP) in Health Economics, Policy and Law
- Vol. 3 (3) , 229-256
- https://doi.org/10.1017/s1744133108004477
Abstract
Despite myriad programs aimed at increasing access to essential medicines in the developing world, the global drug gap persists. This paper focuses on the major legal and political constraints preventing implementation of coordinated global policy solutions – particularly, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and bilateral and regional free trade agreements. We argue that several policy and research routes should be taken to mitigate the restrictive impact of TRIPS and TRIPS-plus rules, including greater use of TRIPS flexibilities, advancement of human rights, and an ethical framework for essential medicines distribution, and a broader campaign that debates the legitimacy of TRIPS and TRIPS-plus standards themselves.Keywords
This publication has 16 references indexed in Scilit:
- Indian Pharma Enters the Global ArenaCell, 2007
- A breath of fresh airNature, 2007
- Reinventing an industryNature, 2007
- Trade Rules, Intellectual Property, and the Right to HealthEthics & International Affairs, 2007
- Public Health and Intellectual Property RightsGlobal Social Policy, 2002
- The pharmaceutical industry as a medicines providerThe Lancet, 2002
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- The Global Drug GapScience, 2000
- The Trips Trade‐OffThe Journal of World Intellectual Property, 1999
- The Effects of Patent Protection on the Prices of Pharmaceutical ProductsThe Journal of World Intellectual Property, 1998